EP1898871A2 - Utilisation de polypeptides d'hydrophobine et de conjugues de polypeptides d'hydrophobine avec des substances actives ou a effet ainsi que leur production et leur application en cosmetique - Google Patents

Utilisation de polypeptides d'hydrophobine et de conjugues de polypeptides d'hydrophobine avec des substances actives ou a effet ainsi que leur production et leur application en cosmetique

Info

Publication number
EP1898871A2
EP1898871A2 EP06777430A EP06777430A EP1898871A2 EP 1898871 A2 EP1898871 A2 EP 1898871A2 EP 06777430 A EP06777430 A EP 06777430A EP 06777430 A EP06777430 A EP 06777430A EP 1898871 A2 EP1898871 A2 EP 1898871A2
Authority
EP
European Patent Office
Prior art keywords
hydrophobin
acid
hair
cosmetic
polypeptide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06777430A
Other languages
German (de)
English (en)
Inventor
Thomas Subkowski
Marvin Karos
Hans-Georg Lemaire
Heiko Barg
Claus Bollschweiler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of EP1898871A2 publication Critical patent/EP1898871A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/002—Aftershave preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair

Definitions

  • Hydrophobins are small proteins of about 100 AA, which are characteristic of filamentous fungi and do not occur in other organisms. Recently, hydrophobin-like proteins have been discovered in Streptomyces coelicolor, also known as "chapliners,” which also have high surface-active properties, and at water-air interfaces can chapline into amyloid-like fibrils (Classen et al., 2003) Genes Dev 1714-1726; Elliot et al., 2003, Genes Dev. 17, 1727-1740).
  • Hydrophobins are in a water-insoluble form on the surface of various fungal structures, e.g. Aerial hyphae, spores, fruiting bodies, distributed.
  • the genes for hydrophobins could be isolated from ascomycetes, deuteromycetes and basidiomycetes.
  • Some fungi contain more than one hydrophobing, e.g. Schizophyllum commune, Coprinus cinereus, Aspergillus nidulans.
  • different hydrophobins are involved in different stages of fungal development. The hydrophobins are believed to be responsible for different functions (van Wetter et al., 2000, Mol. Microbiol., 36, 201-210, Kershaw et al., 1998, Fungal Genet., Biol, 1998, 23, 18-33).
  • hydrophobins As a biological function for hydrophobins, in addition to reducing the surface tension of water to generate aerial hyphae, the hydrophobization of spores is also described (Wösten et al., 1999, Curr. Biol., 19, 1985-88; Bell et al., 1992, Genes Dev., 6, 2382-2394). Hydrophobins also serve to line gas channels in lichen fructoids and as components in the plant surface recognition system by fungal pathogens (Lugones et al., 1999, Mycol Res., 103, 635-640, Hamer & Talbot 1998, Curr. Opinion Microbiol. , Vol. 1, 693-697).
  • hydrophobins can functionally replace to some degree within a class.
  • the hitherto known hydrophobins can be prepared by conventional protein-chemical cleaning and isolation methods only in moderate yield and purity. Even attempts to provide larger amounts of hydrophobins with the aid of genetic engineering have not been successful so far.
  • the object of the present invention was to provide novel polypeptides which have a high affinity for keratin or keratin-containing substances such as skin, nails or hair and / or for mucous membranes and / or teeth.
  • Such polypeptides are suitable for the cosmetic and pharmaceutical treatment of keratin-containing structures, in particular of hair, nails and skin, or of mucous membranes or teeth and as an anchor for a variety of active ingredients and effect substances.
  • Such keratin-binding effector molecules allow a high local concentration of effector molecules on the keratin, i. a so-called "taringing" or a long duration of action on the keratin.
  • the invention relates to cosmetic compositions for the treatment of keratin-containing materials, mucous membranes and teeth, containing at least one hydrophobin polypeptide sequence (i) of the general structural formula (I) in a cosmetically acceptable medium.
  • X is any of the 20 naturally occurring amino acids (Phe, Leu, Ser, Tyr, Cys, Trp, Pro, His, GIn, Arg, Ne Met, Thr, Asn, Lys, VaI, Ala, Asp, Glu, Gly) can and the indices standing at X represent the number of amino acids, the indices n and m being numbers between 0 and 500, preferably between 15 and 300, p being a number between 1 and 250, preferably 1-100, and C is cysteine, alanine, serine, glycine, methionine or threonine, with at least four of the radicals named C being cysteine, with the proviso that at least one of the peptide sequences abbreviated by X n or X n , or X p represents at least 20 Is amino acid-long peptide sequence, which is not naturally associated with a hydrophobin, which cause a contact angle change of at least 20 ° after coating a glass surface.
  • the amino acids designated C 1 to C 8 are preferably cysteines; but they can also be replaced by other amino acids of similar space filling, preferably by alanine, serine, threonine, methionine or glycine. However, at least four, preferably at least 5, more preferably at least 6 and in particular at least 7, of the positions C 1 to C 8 should consist of cysteines. Cysteines can either be reduced in the proteins according to the invention or form disulfide bridges with one another. Particularly preferred is the intramolecular formation of CC bridges, in particular those having at least one, preferably 2, more preferably 3 and most preferably 4 intramolecular disulfide bridges. In the exchange of cysteines described above by amino acids of similar space filling, it is advantageous to exchange in pairs those C positions which are capable of forming intramolecular disulfide bridges with one another.
  • cysteines, serines, alanines, glycines, methionines or threonines are also used in the positions indicated by X, the numbering of the individual C-positions in the general formulas may change accordingly.
  • polypeptides (i) are those of the general formula (II)
  • X is any of the 20 naturally occurring amino acids (Phe, Leu, Ser, Tyr, Cys, Trp, Pro, His, GIn, Arg, Ne Met, Thr, Asn, Lys, VaI, Ala, Asp, Glu, Gly) and the indices standing at X represent the number of amino acids, the indices n and m being numbers between 2 and 300, and C being cysteine, alanine, serine, glycine, methionine or threonine, at least four of which are designated C.
  • Residues for cysteine with the proviso that at least one of the peptide sequences abbreviated to X n or X m stands for a peptide sequence which is at least 35 amino acids long and which is not naturally linked to a hydrophobin which, after coating a glass surface, changes the contact angle - effect at least 20 °.
  • X is any of the 20 naturally occurring amino acids (Phe, Leu, Ser, Tyr, Cys, Trp, Pro, His, GIn, Arg, Ne Met, Thr, Asn, Lys, VaI, Ala, Asp, Glu, Gly) and the indices standing at X represent the number of amino acids, the indices n and m being numbers between 0 and 200, and C being cysteine, alanine, serine, glycine, methionine or threonine, at least six of which are denoted by C with the proviso that at least one of the peptide sequences abbreviated to X n or X m represents a peptide sequence of at least 40 amino acids that is not naturally linked to a hydrophobin which, after coating a glass surface, changes the contact angle of cause at least 20 °.
  • the hydrophobins mentioned are structurally characterized in the sequence listing below. It is also possible to link together a plurality of hydrophobins, preferably 2 or 3, of the same or different structure and to link them to a corresponding suitable polypeptide sequence which is not naturally associated with a hydrophobin.
  • proteins having the polypeptide sequences shown in SEQ ID NO: 20, 22, 24 and the nucleic acid sequences coding therefor, in particular the sequences according to SEQ ID NO: 19, 21, 23.
  • proteins which are starting from those shown in SEQ ID NO. 22, 22 or 24 represented polypeptide sequences by exchange, insertion or deletion of at least one, up to 10, preferably 5, particularly preferably 5% of all amino acids, and still possess at least 50% of the biological property of the starting proteins are particularly preferred embodiments.
  • the biological property of the proteins is understood to mean the change in the contact angle as described in Example 10.
  • the proteins according to the invention carry at least one position which is abbreviated X n or X m or X p , a polypeptide sequence of at least 20, preferably at least 35, more preferably at least 50 and especially at least 100 amino acids (also referred to below as fusion partners) which are not more natural - Is linked to a hydrophobin.
  • X n or X m or X p a polypeptide sequence of at least 20, preferably at least 35, more preferably at least 50 and especially at least 100 amino acids (also referred to below as fusion partners) which are not more natural - Is linked to a hydrophobin.
  • the fusion partner portion can be selected from a variety of proteins. It is also possible to link a plurality of fusion partners with a hydrophobin part, for example at the amino terminus (X n ) and at the carboxy terminus (X n ,) of the hydrophobin part. However, it is also possible, for example, to link two fusion partners with a position (X n or X n ,) of the protein according to the invention.
  • Particularly preferred fusion partners are those polypeptide sequences which result in the protein according to the invention being able to coat glass surfaces and the protein-treated glass surface becoming resistant to a detergent treatment as described in detail in the experimental part (Example 10) (eg 1%). SDS / 80 ° C / 10 min).
  • fusion partners are polypeptides that occur naturally in microorganisms, in particular in E. coli or Bacillus subtilis.
  • fusion partners are the sequences yaad (SEQ ID NO: 15 and 16), yaae (SEQ ID NO: 17 and 18), and thioredoxin.
  • fragments or derivatives of said sequences which comprise only a part, preferably 10-90%, particularly preferably 25-75% of said sequences.
  • a deletion at the C-terminal end is preferred; for example, a yaad fragment which consists only of the first 75 N-terminal amino acids, or in which individual amino acids, or nucleotides are changed from the said sequence.
  • additional amino acids in particular two additional amino acids, preferably the amino acids Arg, Ser, can be added at the C-terminal end of the sequences yaad and yaae.
  • additional amino acids may be preferred be inserted opposite to the naturally occurring sequence, for example, the amino acid no. 2 (Gly) in SEQ ID NO: 17 and 18.
  • keratin binding domains for example those which occur in the human desmoplakin or which can be derived from them by conventional genetic engineering methods such as amino acid substitution, insertion or deletion. The binding to keratin can be easily checked with the experiments described in the experimental section.
  • amino acids can also be inserted at the junctions of two fusion partners, which result from the fact that recognition sites for restriction endonucleases are either newly created or inactivated at the nucleic acid level.
  • proteins according to the invention may also be modified in their polypeptide sequence, for example by glycosylation, acetylation or else by chemical crosslinking, for example with glutaraldehyde.
  • a characteristic of the proteins according to the invention is the change of surface properties when the surfaces are coated with the proteins.
  • the change in the surface properties can be determined experimentally by measuring the contact angle of a water drop before and after coating the surface with the protein according to the invention and determining the difference between the two measurements.
  • the proteins according to the invention have the property of increasing the contact angle by at least 20, preferably 25, more preferably 30 degrees.
  • a comparison of the amino acid sequences shows that the length of the region between cysteine C 3 and C 4 in class II hydrophobins is significantly shorter than in class I hydrophobins.
  • Class II hydrophobins continue to have more charged amino acids than Class I.
  • the hydrophobin (i) can be represented by all known hydrophobin polypeptides.
  • Particularly suitable hydrophobins (i) are the abovementioned polypeptides (i) of the general structural formula (I), (II) or (III).
  • Preferred hydrophobin polypeptide sequences (i) comprise an amino acid sequence according to SEQ ID NO: 1-24.
  • hydrophobin polypeptide sequences (i) are also included within the scope of the invention.
  • “Functional equivalents” or analogues of the specifically disclosed polypeptides (i) are, within the scope of the present invention, different polypeptides which furthermore possess the desired biological activity, such as, for example, keratin binding
  • hydrophobin polypeptide sequences which exhibit at least 10% binding according to one of the binding assays described in Examples 12/13, preferably at least 50%, more preferably 75%, most preferably 90% of the binding which is a Hy - shows drophobin of SEQ ID NO: 1-24 in the binding assays according to Examples 12/13.
  • Precursors are natural or synthetic precursors of the polypeptides with or without desired biological activity.
  • Salts are understood as meaning both salts of carboxyl groups and acid addition salts of amino groups of the protein molecules of the invention
  • Salts of carboxyl groups can be prepared in a manner known per se and include inorganic salts such as, for example, sodium, calcium, ammonium, iron and zinc salts, as well as salts with organic bases such as amines such as triethanolamine, arginine, lysine, piperidine and the like, acid addition salts such as salts with mineral acids such as hydrochloric acid or sulfuric acid and salts with organic acids such as acetic acid and oxalic acid also the subject of the invention.
  • inorganic salts such as, for example, sodium, calcium, ammonium, iron and zinc salts
  • organic bases such as amines such as triethanolamine, arginine, lysine, piperidine and the like
  • acid addition salts such as salts with mineral acids such as hydrochloric acid or sulfuric acid and salts with organic acids such as acetic acid and
  • “Functional derivatives” of polypeptides of the invention may also be produced at functional amino acid side groups or at their N- or C-terminal end by known techniques
  • Such derivatives include, for example, aliphatic esters of carboxylic acid groups, amides of carboxylic acid groups obtainable by reaction with ammonia or with a primary or secondary amine; N-acyl derivatives of free amino groups prepared by reaction with acyl groups; or O-acyl derivatives of free hydroxy groups prepared by reacting with acyl groups.
  • “functional equivalents” also encompass polypeptides that are accessible from other organisms, as well as naturally occurring variants. For example, it is possible to determine regions of homologous sequence regions by sequence comparison and to determine equivalent enzymes on the basis of the specific requirements of the invention.
  • “Functional equivalents” likewise include fragments, preferably individual domains or sequence motifs, of the polypeptides according to the invention which, for example, have the desired biological function.
  • “Functional equivalents” are also fusion proteins which comprise one of the abovementioned hydrophobin polypeptide sequences or functional equivalents derived therefrom and at least one further, functionally different, heterologous sequence in functional N- or C-terminal linkage (ie without substantial mutual functional impairment
  • Nonlimiting examples of such heterologous sequences are, for example, signal peptides or enzymes.
  • homologs to the specifically disclosed proteins which have at least 50%, preferably at least 75%, in particular at least 85%, such as 90%, 95% or 99%, homology to one of the specifically disclosed amino acid sequences, Calculated according to the algorithm of Pearson and Lipman, Proc Natl Acad., U.S.A., 85 (8), 1988, 2444-2448
  • a percent homology of a homologous polypeptide of the invention means, in particular, percent identity of the amino acid residues relative to the total length of one of specifically described herein.
  • “functional equivalents” include proteins of the type described above in deglycosylated or glycosylated form as well as modified forms obtainable by altering the glycosylation pattern.
  • Homologs of the polypeptides (i) of the invention may be generated by mutagenesis, e.g. by point mutation or shortening of the protein.
  • Homologs of the polypeptides of the invention can be identified by screening combinatorial libraries of mutants such as truncation mutants.
  • a library of protein variants can be generated by combinatorial mutagenesis at the nucleic acid level, such as by enzymatic ligation of a mixture of synthetic oligonucleotides.
  • methods that can be used to prepare libraries of potential homologs from a degenerate oligonucleotide sequence. The chemical synthesis of a degenerate gene sequence can be performed in a DNA synthesizer, and the synthetic gene can then be ligated into a suitable expression vector.
  • degenerate gene set allows for the provision of all sequences in a mixture containing the desired set of potential protein sequences. encode frequencies.
  • Methods of synthesizing degenerate oligonucleotides are known to those skilled in the art (eg, Narang, SA (1983) Tetrahedron 39: 3; Itakura et al. (1984) Annu. Rev. Biochem. 53: 323; Itakura et al., (1984) Science 198: 1056; Ike et al. (1983) Nucleic Acids Res. 11: 477).
  • REM Recursive ensemble mutagenesis
  • hydrophobin-containing effector molecules in which the hydrophobin is represented by a polypeptide sequence (i) which comprises at least one of the following hydrophobin polypeptide sequences,
  • polypeptide sequence which is changed in relation to (a) in up to 60%, preferably up to 75%, particularly preferred up to 90% of the amino acid positions,
  • the keratin binding of the hydrophobin polypeptide sequence (b) is at least 10% of the value exhibited by the hydrophobin polypeptide sequence (a) measured in the assay of Examples 12 and 13, respectively.
  • altering amino acids is meant amino acid substitutions, insertions and deletions or any combination of these three possibilities.
  • hydrophobin polypeptide sequences (i) are used which have a highly specific affinity for the desired organism.
  • hydrophobin polypeptide sequences (i) are preferably used which have a particularly high affinity for the human dermal keratin.
  • hydrophobin polypeptide sequences (i) which have a particularly high affinity for the corresponding keratin, for example, dog keratin or cat keratin.
  • hydrophobin polypeptide sequence (i) in the effector molecule according to the invention.
  • multiple copies of the same hydrophobin polypeptide sequence (i) can be switched in tandem to achieve, for example, higher binding.
  • hydrophobins according to the invention having keratin-binding properties have a wide field of application in human cosmetics, in particular skin and hair care, animal care.
  • hydrophobin polypeptides (i) according to the invention are preferably used for hair and skin cosmetics. They allow a high concentration and long duration of action of skin-care or skin-protecting effector substances.
  • effector molecules (ii) are understood in the following molecules having a certain predictable effect. These can be either proteinaceous molecules, such as enzymes or else non-proteinogenic molecules such as dyes, light stabilizers, vitamins and fatty acids, or metal ion-containing compounds.
  • enzymes and antibodies are preferred.
  • the enzymes the following are preferred as effector molecules (ii): oxidases, peroxidases, proteases, tyrosinases, metal-binding enzymes, lactoperoxidase, lysozyme, amyloglycosidase, glucose oxidase, superoxide dismutase, photolyase, calalase.
  • Hydrolysates of proteins from plant and animal sources for example hydrolyzates of proteins of marine origin or silk hydrolysates, are also very suitable as proteinaceous effector molecules (ii).
  • non-proteinaceous effector molecules (ii) dyes such as semipermanent dyes or oxidation dyes are preferred.
  • a component is preferably linked as effector molecule (ii) with the keratin-binding hydrophobin polypeptide sequence (i) and then at the site of action, i. after attachment to the hair, oxidatively coupled with the second dye component.
  • Suitable dyestuffs are all customary hair dyestuffs for the molecules according to the invention. Suitable dyes are the expert from manuals of cosmetics such as Schrader, bases and formulations of cosmetics, Weghig Verlag, Heidelberg, 1989, ISBN 3-7785-1491-1 known.
  • carotenoids are to be understood as meaning the following compounds: ⁇ -carotene, lycopene, lutein, astaxanthin, zeaxanthin, cryptoxanthin, citranaxanthin, canthaxanthin, bixin, ⁇ -apo-4-carotenal, ⁇ -apo-8-carotenal, ⁇ -apo -8-carotenoic acid ester, singly or as a mixture.
  • carotenoids are ⁇ -carotene, lycopene, lutein, astaxanthin, zeaxanthin, citranaxanthin and canthaxanthin.
  • retinoids in the context of the present invention is meant vitamin A alcohol (retinol) and its derivatives such as vitamin A aldehyde (retinal), vitamin A acid (retinoic acid) and vitamin A esters (e.g., retinyl acetate, retinyl propionate and retinyl palmitate).
  • retinoic acid encompasses both all-trans retinoic acid and 13-cis retinoic acid.
  • the terms retinol and retinal preferably include the all-trans compounds.
  • the preferred retinoid used for the suspensions of the invention all-trans-retinol, hereinafter referred to as retinol.
  • effector molecules (ii) are vitamins, especially vitamin A and their esters.
  • Vitamins, provitamins and vitamin precursors from groups A, C, E and F in particular 3,4-didehydroretinol, ß-carotene (provitamin of vitamin A), ascorbic acid
  • vitamin C the palmitic acid esters, glucosides or phosphates of ascorbic acid, tocopherols, in particular ⁇ -tocopherol and its esters, for example the acetate, the Nicotinate, the phosphate and the succinate; vitamin F, which is understood as meaning essential fatty acids, especially linoleic acid, linolenic acid and arachidonic acid;
  • Vitamin A and its derivatives and provitamins advantageously show a particular skin-smoothing effect.
  • vitamins, provitamins or vitamin precursors of the vitamin B group or derivatives thereof which are preferably to be used according to the invention and the derivatives of 2-furanone include, inter alia:
  • Vitamin B 1 common name thiamin, chemical name 3 - [(4'-amino-2'-methyl-5'-pyrimidyl) methyl] -5- (2-hydroxyethyl) -4-methylthiazole iu mch Lorid.
  • Vitamin B 2 trivial name riboflavin, chemical name 7,8-dimethyl-10- (1-D-ribityl) -benzo [g] pteridine-2,4 (3H, 10H) -dione.
  • riboflavin z As in whey, other riboflavin derivatives can be isolated from bacteria and yeasts.
  • a stereoisomer of riboflavin which is also suitable according to the invention is lyxoflavin which can be isolated from fishmeal or liver and carries a D-arabityl residue instead of D-ribityl.
  • Vitamin B 3 Vitamin B 3 .
  • the compounds nicotinic acid and nicotinamide (niacinamide) are often performed.
  • the nicotinic acid amide is preferred.
  • Vitamin B 5 pantothenic acid and panthenol.
  • Panthenol is preferably used.
  • Derivatives of panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and also cationically derivatized panthenols.
  • Particularly preferred derivatives are the commercially available substances dihydro-3-hydroxy-4,4-dimethyl-2 (3H) -furanone with the trivial name pantolactone (Merck), 4 hydroxymethyl- ⁇ -butyrolactone (Merck), 3,3-dimethyl 2-hydroxy- ⁇ -butyrolactone (Aldrich) and 2,5-dihydro-5-methoxy-2-furanone (Merck), expressly including all stereoisomers.
  • Vitamin B 6 which is understood here not a single substance, but the known under the common names pyridoxine, pyridoxamine and pyridoxal derivatives of 5-hydroxymethyl-2-methylpyridin-3-ols.
  • Vitamin B 7 also known as vitamin H or "skin vitamin”.
  • Biotin is (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-d] imidazole-4-valeric acid.
  • Panthenol, pantolactone, nicotinamide and biotin are very particularly preferred according to the invention.
  • suitable derivatives salts, esters, sugars, nucleotides, nucleosides, peptides and lipids.
  • Preferred lipophilic, oil-soluble antioxidants from this group are tocopherol and its derivatives, gallic acid esters, flavonoids and carotenoids, and butylhydroxytoluene / anisole.
  • water-soluble antioxidants are amino acids, eg. As tyrosine and cysteine and their derivatives and tanning agents, especially those of plant origin are preferred.
  • Triterpenes in particular triterpenic acids such as ursolic acid, rosmarinic acid, betulinic acid, boswellic acid and brononolic acid.
  • Further preferred effector molecules (ii) are UV light protection filters.
  • organic substances capable of absorbing ultraviolet rays and absorbing the absorbed energy in the form of longer wavelength radiation, e.g. Heat, give it up again.
  • the organic substances may be oil-soluble or water-soluble.
  • oil-soluble UV-B filters e.g. the following substances are used:
  • 4-aminobenzoic acid derivatives preferably 2-ethylhexyl 4- (dimethylamino) benzoate, 2-octyl 4- (dimethylamino) benzoate and 4- (dimethylamino) benzoic acid ester;
  • esters of cinnamic acid preferably 2-ethylhexyl 4-methoxycinnamate, 4-propyl methoxy cinnamate, isoamyl 4-methoxycinnamate, 4-isoacetyl methoxycinnamate, 2-cyano-3-phenylcinnamic acid 2-ethylhexyl ester (octocrylene);
  • Esters of acidic acid preferably 2-ethylhexyl salicylate, 4-isopropylbenzyl salicylate, homomenthyl salicylate;
  • Derivatives of benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy- 1- methoxy- 1 -methylbenzophenone, 2,2-dihydroxy-4-methoxybenzophenone;
  • Esters of benzalmalonic acid preferably di-2-ethylhexyl 4-methoxybenzmalonate
  • Triazine derivatives such as 2 J 4 J 6-trianilino- (p-carbo-2 l -ethyl-r-hexyloxy) -1,3 J 5-triazine (octyl tyltriazone) and Dioctyl Butamido Triazone (Uvasorb HEB ®):
  • Propane-1,3-diones such as e.g. 1 - (4-tert-butylphenyl) -S-3'-methoxyphenylpropane-1-dione.
  • Suitable water-soluble substances are:
  • Sulfonic acid derivatives of benzophenones preferably 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its salts;
  • Sulfonic acid derivatives of the 3-benzylidene camphor e.g. 4- (2-oxo-3-bomylidenemethyl) benzenesulfonic acid and 2-methyl-5- (2-oxo-3-bomylidene) -sulfonic acid and its salts.
  • esters of cinnamic acid preferably 4-methoxycinnamic acid 2-ethylhexyl ester, 4-methoxycinnamic acid isopentyl ester, 2-cyano-3-phenylcinnamic acid 2-ethylhexyl ester (octocrylene).
  • Typical UV-A filters are:
  • benzoylmethane for example 1- (4'-tert-butylphenyl) -3- (4 1 - methoxyphenyl) propane-1,3-dione, 4-tert-butyl-4'-methoxydibenzoylmethane or 1-phenyl-3 - (4'-isopropylphenyl) -propane-1,3-dione;
  • UV-A and UV-B filters can also be used in mixtures.
  • insoluble pigments e.g. finely disperse metal oxides or salts such as titanium dioxide, iron oxide, aluminum oxide, cerium oxide, zirconium oxide, silicates (talc), barium sulfate and zinc stearate.
  • the particles should have an average diameter of less than 100 nm, preferably between 5 and 50 nm and in particular between 15 and 30 nm.
  • secondary light stabilizers of the antioxidant type which interrupt the photochemical reaction chain which is triggered when UV radiation penetrates into the skin.
  • Typical examples are superoxide dismutase, catalase, tocopherols (vitamin E) and ascorbic acid (vitamin C).
  • anti-irritants which have an anti-inflammatory effect on UV-damaged skin.
  • anti-irritants which have an anti-inflammatory effect on UV-damaged skin.
  • Such substances are, for example, bisabolol, phytol and phytantriol.
  • the effector molecules (ii) are linked to a hydrophobin polypeptide sequence (i) which has a binding affinity to a keratin.
  • the connection between (i) and (ii) can be based both covalently and on ionic or van-der Waals interactions ( Figure 3).
  • the linkage of the effector molecules (ii) with the hydrophobin polypeptide sequence (i) can be either directly, ie as a covalent linkage of two in (i) and (ii) already existing chemical functions, for example, an amino function of (i) with a carboxylate function of (ii) linked to the acid amide.
  • the linkage can also take place via a so-called linker, ie an at least bifunctional molecule which, with one function, enters into a bond with (i) and is linked to another function by (ii).
  • effector molecule (ii) also consists of a polypeptide sequence
  • linkage of (i) and (ii) can be effected by a so-called fusion protein, ie a continuous polypeptide sequence consisting of the two partial sequences (i) and (ii).
  • spacer elements between (i) and (ii), for example polypeptide sequences which have a potential cleavage site for a protease, lipase, esterase, phosphatase, hydrolase or polypeptide sequences which permit easy purification of the fusion protein, for example called His-tags, ie Oligohistidinreste.
  • the linkage in the case of a non-proteinaceous effector molecule with the hydrophobin polypeptide sequence (i) is preferably carried out by functionalizable groups (side groups) on the hydrophobin polypeptide (i) which form a covalent bond with a chemical function of the effector molecule.
  • Preferred here is the bond formation via an amino, thiol or hydroxyl function of the hydrophobin polypeptide (i), which can enter into a corresponding amide, thioester or ester bond, for example with a carboxyl function of the effector molecule (ii), if appropriate after activation.
  • Another preferred linkage of the hydrophobin polypeptide sequence (i) with an effector molecule (ii) is the use of a tailor-made linker.
  • a linker has two or more so-called anchor groups with which it can link the hydrophobin polypeptide sequence (i) and one or more effector molecules (ii).
  • an anchor group for (i) may be a thiol function by which the linker may form a disulfide bond with a cysteine residue of the polypeptide (i).
  • An anchor group for (ii) can be, for example, a carboxyl function, by means of which the linker can enter into an ester bond with a hydroxyl function of the effector molecule (ii).
  • linker used depends on the functionality to be coupled.
  • suitable molecules are those which couple to polypeptides (i) by means of sulfhydryl-reactive groups, for example maleimides, pyridyl disulfides, ⁇ -haloacetyls, vinyl sulfone and to effector molecules (ii) Sulfhydryl-reactive groups, for example maleimides, pydridyl disulfides, ⁇ -haloacetyls, vinyl sulfones) amine-reactive groups (eg succinimidyl esters, carbodiimde, hydroxymethyl-phosphine, imidoesters, PFP esters, etc.) sugars or oxidized sugar-reactive groups (eg hydrazides etc.) - carboxy-reactive groups (eg carbodiimides etc.) hydroxyl-reactive groups (eg isocyanates etc.) thymine-reactive groups (eg psoralen etc
  • Antibodies and fragments e.g., single-chain antibodies, F (ab) fragments of antibodies, catalytic antibodies.
  • a direct coupling between active / effect substance and the keratin binding domain can be e.g. by means of carbodiimides, glutaric dialdehyde or other crosslinkers known to the person skilled in the art.
  • the linker may be stable, thermo gapable, photocleavable or enzymatically cleavable (especially by lipases, esterases, proteases, phosphatases, hydrolases, etc.). Corresponding chemical structures are known to the person skilled in the art and are integrated between the moieties (i) and (ii).
  • novel keratin-binding hydrophobin effector molecules have a wide field of application in human cosmetics, in particular skin and hair care, animal care.
  • the keratin-binding hydrophobin effector molecules according to the invention are preferably used for dermal, nail and hair cosmetics. They allow a high concentration and long duration of action of skin, nail and hair care or skin, nail and hair protecting effector.
  • Suitable auxiliaries and additives for the production of hair cosmetic or skin cosmetic preparations are familiar to the expert and can from manuals of cosmetics, such as Schrader, bases and formulations of cosmetics, Weghig Verlag, Heidelberg, 1989, ISBN 3-7785-1491-1, taken become.
  • the cosmetic agents according to the invention may be skin-cosmetic, hair-cosmetic, dermatological, hygienic or pharmaceutical agents.
  • the agents according to the invention are preferably in the form of a gel, foam, spray, ointment, cream, emulsion, suspension, lotion, milk or paste. If desired, liposomes or microspheres can also be used.
  • the cosmetically or pharmaceutically active agents according to the invention may additionally contain cosmetically and / or dermatologically active agents as well as excipients.
  • the cosmetic compositions according to the invention contain at least one hydrophobin polypeptide sequence (i) as defined above, and at least one different constituent selected from cosmetically active substances, emulsifiers, surfactants, preservatives, perfume oils, thickeners,
  • Typical thickeners in such formulations are crosslinked polyacrylic acids and their derivatives, polysaccharides and their derivatives, such as xanthan gum, agar-agar, alginates or tyloses, cellulose derivatives, e.g. Carboxymethylcellulose or hydroxycarboxymethylcellulose, fatty alcohols, monoglycerides and fatty acids, polyvinyl alcohol and polyvinylpyrrolidone.
  • Nonionic thickeners are preferably used.
  • Suitable cosmetically and / or dermatologically active substances are, for example, coloring agents, skin and hair pigmenting agents, tinting agents, suntanning agents, bleaching agents, keratin-hardening substances, antimicrobial agents, light filter active ingredients, repellent active ingredients, hyperemic substances, keratolytic and keratoplasmic substances, antidandruff active ingredients, Antiphlogistics, keratinizing substances, antioxidants or radical scavengers active ingredients, skin moisturizing or moisturizing substances, moisturizing agents, anti-erythematous or anti-allergic active ingredients and mixtures thereof.
  • Artificial skin tanning agents which are suitable for tanning the skin without natural or artificial UV rays are, for example, dihydroxyacetone, alloxan and walnut shale extract.
  • Suitable keratin-hardening substances are as a rule active substances, as are also used in antiperspirants, for example potassium aluminum sulfate, aluminum hydroxychloride, aluminum lactate, etc.
  • Antimicrobial agents are used to destroy microorganisms or to inhibit their growth and thus serve both as a preservative and as a deodorizing substance, which reduces the formation or intensity of body odor.
  • These include e.g. conventional preservatives known to those skilled in the art, such as p-hydroxybenzoic acid esters, imidazolidinyl urea, formaldehyde, sorbic acid, benzoic acid, salicylic acid, etc.
  • deodorizing substances are e.g. Zinc ricinoleate, triclosan, undecylenic acid alkylolamides, citric acid triethyl ester, chlorhexidine etc.
  • Suitable light filter active substances are substances which absorb UV rays in the UV-B and / or UV-A range.
  • Suitable UV filters are e.g. 2,4,6-triaryl-1,3,5-triazines in which the aryl groups can each bear at least one substituent, which is preferably selected from hydroxy, alkoxy, especially methoxy, alkoxycarbonyl, especially methoxycarbonyl and ethoxycarbonyl and mixtures thereof.
  • substituent which is preferably selected from hydroxy, alkoxy, especially methoxy, alkoxycarbonyl, especially methoxycarbonyl and ethoxycarbonyl and mixtures thereof.
  • p-aminobenzoic acid esters cinnamic acid esters, benzophenones, camphor derivatives and UV-radiation-stopping pigments, such as titanium dioxide, talc and zinc oxide.
  • Suitable repellent agents are compounds which are able to prevent or expel certain animals, in particular insects, from humans. These include, for example, 2-ethyl-1, 3-hexanediol, N, N-diethyl-m-toluamide, etc.
  • Suitable hyperemic substances which stimulate the circulation of the skin are, for example, essential oils, such as mountain pine extract, lavender extract, rosemary extract, juniper berry extract, Horse chestnut extract, birch leaf extract, hay flower extract, ethyl acetate, camphor, menthol, peppermint oil, rosemary extract, eucalyptus oil, etc.
  • Suitable keratolytic and keratoplastic substances are, for example, salicylic acid, calcium thioglycolate, thioglycollic acid and its salts, sulfur, etc.
  • Suitable antidandruff active substances are, for example, sulfur Sulfur polyethylene glycol sorbitan monooleate, sulfur ricinol polyethoxylate, zinc pyrithione, aluminum pyrithione, etc.
  • Suitable antiphlogistic agents which counteract the effects on the skin are, for example, allantoin, bisabolol, dragosantol, chamomile extract, panthenol, etc.
  • the cosmetic agents according to the invention may contain as cosmetic and / or pharmaceutical active ingredient (as well as optionally as adjuvant) at least one cosmetically or pharmaceutically acceptable polymer which differs from the polymers which form the polyelectrolyte complex used according to the invention.
  • cosmetically or pharmaceutically acceptable polymer which differs from the polymers which form the polyelectrolyte complex used according to the invention.
  • These include, in general, cationic, amphoteric and neutral polymers.
  • Suitable polymers are e.g. cationic polymers called polyquaternium according to INCI, e.g. Copolymers of vinylpyrrolidone / N-vinylimidazolium salts (Luviquat FC, Luviquat HM, Luviquat MS, Luviquat & commat, Care), copolymers of N-vinylpyrrolidone / dimethylaminoethyl methacrylate, quaternized with diethyl sulfate (Luviquat PQ 11), copolymers of N-vinylcaprolactam / N-vinylpyrrolidone / N-vinylimidazolium salts (Luviquat E Hold), cationic cellulose derivatives (polyquaternium-4 and -10), acrylamidocopolymers (Polyquatemium-7) and chitosan.
  • polyquaternium cationic polymers called polyquaternium according to INCI,
  • Suitable cationic (quaternized) polymers are also merquat (dimethyldiallylammonium chloride based polymer), gafquat (quaternary polymers formed by reaction of polyvinylpyrrolidone with quaternary ammonium compounds), polymer JR (hydroxyethylcellulose with cationic groups), and plant based cationic polymers, e.g. Guarpolymers, such as the Jaguar brands of Rhodia.
  • polystyrene resins are also neutral polymers, such as polyvinylpyrrolidones, copolymers of N-vinylpyrrolidone and vinyl acetate and / or vinyl propionate, polysiloxanes, polyvinylcaprolactam and other copolymers with N-vinylpyrrolidone, polyethylenimines and their salts, polyvinylamines and their salts, cellulose derivatives, Polyasparaginic acid salts and derivatives.
  • neutral polymers such as polyvinylpyrrolidones, copolymers of N-vinylpyrrolidone and vinyl acetate and / or vinyl propionate, polysiloxanes, polyvinylcaprolactam and other copolymers with N-vinylpyrrolidone, polyethylenimines and their salts, polyvinylamines and their salts, cellulose derivatives, Polyasparaginic acid salts and derivatives.
  • Suitable polymers are also nonionic, water-soluble or water-dispersible polymers or oligomers, such as polyvinylcaprolactam, e.g. Luviskol 0 Plus (BASF), or polyvinylpyrrolidone and their copolymers, in particular with vinyl esters, such as vinyl acetate, e.g. Luviskol 0 VA 37 (BASF), polyamides, e.g. based on itaconic acid and aliphatic diamines, e.g. in DE-A-43 33 238 are described.
  • polyvinylcaprolactam e.g. Luviskol 0 Plus (BASF)
  • BASF Luviskol 0 VA 37
  • polyamides e.g. based on itaconic acid and aliphatic diamines, e.g. in DE-A-43 33 238 are described.
  • Suitable polymers are also amphoteric or zwitterionic polymers, such as the octylacrylamide / methyl methacrylate / tert.-butylaminoethyl methacrylate-hydroxypropyl methacrylate copolymers available under the names Amphomer (National Starch) and zwitterionic polymers, as described, for example, in the German patent application. fertil DE39 29 973, DE 21 50 557, DE 28 17 369 and DE 3708 451 are disclosed. Acrylamidopropyltrimethylannnnoniunnchlorid / acrylic acid respectively. Methacrylic acid copolymers and their alkali metal and ammonium salts are preferred zwitterionic polymers.
  • zwitterionic polymers are methacroylethylbetaine / methacrylate copolymers, which are commercially available under the name Amersette (AMERCHOL), and copolymers of hydroxyethyl methacrylate, methyl methacrylate, N, N-dimethylaminoethyl methacrylate and acrylic acid (Jordapon (D)).
  • Suitable polymers are also nonionic, siloxane-containing, water-soluble or -dispersible polymers, e.g. Polyether siloxanes, such as Tegopren 0 (Goldschmidt) or Besi & commat (Wacker).
  • Polyether siloxanes such as Tegopren 0 (Goldschmidt) or Besi & commat (Wacker).
  • the formulation base of pharmaceutical agents according to the invention preferably contains pharmaceutically acceptable excipients.
  • Pharmaceutically acceptable excipients which are known in the pharmaceutical, food technology and related fields, in particular those listed in relevant pharmacopoeias (eg DAB Ph. Eur. BP NF) and other excipients whose properties do not preclude physiological application.
  • Suitable auxiliaries may be: lubricants, wetting agents, emulsifying and suspending agents, preserving agents, antioxidants, anti-irritants, chelating agents, emulsion stabilizers, film formers, gelling agents, odor masking agents, resins, hydrocolloids, solvents, solubilizers, neutralizing agents, permeation accelerators, pigments, quaternary ammonium compounds, Rest grease and superfatting agents, ointment, cream or oil bases, silicone derivatives, stabilizers, sterilants, blowing agents, drying agents, opacifiers, thickeners, waxes, softeners, white oil.
  • a related embodiment is based on expert knowledge, as for example in Fiedler, H. P. Lexicon of excipients for pharmacy, cosmetics and related fields, 4th ed., Aulendorf: ECV Editio Kantor Verlag, 1996, are shown.
  • the active ingredients may be mixed or diluted with a suitable excipient (excipient).
  • Excipients may be solid, semi-solid or liquid materials which may serve as a vehicle, carrier or medium for the active ingredient. If desired, the admixing of further auxiliaries takes place in the manner known to the person skilled in the art.
  • the polymers and dispersions are suitable as auxiliaries in pharmacy, preferably as or in Coating agent (s) or binder (s) for solid dosage forms. They can also be used in creams and as tablet coatings and tablet binders.
  • the agents according to the invention are a skin cleanser.
  • Preferred skin cleansing agents are soaps of liquid to gelatinous consistency, such as transparent soaps, luxury soaps, deep soaps, cream soaps, baby soaps, skin soaps, abrasive soaps and syndets, pasty soaps, greases and washes, liquid detergents, bath and shower preparations such as washing lotions, shower baths and gels, bubble baths, oil baths and scrub preparations, shaving creams, lotions and creams.
  • the agents according to the invention are cosmetic agents for the care and protection of the skin, nail care preparations or preparations for decorative cosmetics.
  • Suitable skin cosmetic agents are e.g. Face lotions, face masks, deodorants and other cosmetic lotions.
  • Means for use in decorative cosmetics include, for example, masking pens, theatrical paints, mascara and eye shadows, lipsticks, kohl pencils, eyeliners, rouges, powders, and eyebrow pencils.
  • hydrophobin polypeptide sequences (i) can be used in nasal strips for pore cleansing, in anti-acne agents, repellents, shaving agents, hair removers, personal care products, foot care products and in baby care.
  • the skin care compositions according to the invention are in particular W / O or O / W skin creams, day and night creams, eye creams, face creams, anti-wrinkle creams, moisturizing creams, bleaching creams, vitamin creams, skin lotions, skin lotions and moisturizing lotions.
  • Skin cosmetic and dermatological compositions based on the above-described polyelectrolyte complexes show advantageous effects.
  • the polymers can contribute to the moisturizing and conditioning of the skin and to the improvement of the skin feel.
  • the polymers may also act as thickeners in the formulations.
  • By adding the polymers of the invention can be achieved in certain formulations, a significant improvement in skin compatibility.
  • Skin cosmetic and dermatological agents preferably contain at least one hydrophobin polypeptide sequence (i) in a proportion of about 0.000001 to 10% by weight, preferably 0.0001 to 1% by weight, based on the total weight of the composition.
  • Particularly light stabilizers based on the hydrophobin polypeptide sequences (i) have the property to increase the residence time of the UV-absorbing ingredients in comparison to conventional adjuvants such as polyvinylpyrrolidone.
  • compositions according to the invention may be in a form suitable for skin care, such as e.g. as a cream, foam, gel, pen, mousse, milk, spray (pump spray or propellant spray) or lotion can be applied.
  • skin care such as e.g. as a cream, foam, gel, pen, mousse, milk, spray (pump spray or propellant spray) or lotion can be applied.
  • the skin cosmetic preparations may contain other active ingredients and adjuvants customary in skin cosmetics, as described above. These preferably include emulsifiers, preservatives, perfume oils, cosmetic active ingredients such as phytantriol, vitamins A, E and C, retinol, bisabolol, panthenol, light stabilizers, bleaching agents, colorants, tinting agents, tanning agents, collagen, protein hydrolysates, stabilizers, pH regulators , Dyes, salts, thickeners, gelling agents, bodying agents, silicones, humectants, moisturizers and other common additives.
  • active ingredients and adjuvants customary in skin cosmetics, as described above. These preferably include emulsifiers, preservatives, perfume oils, cosmetic active ingredients such as phytantriol, vitamins A, E and C, retinol, bisabolol, panthenol, light stabilizers, bleaching agents, colorants, tinting agents, tanning agents, collagen, protein hydrolys
  • Preferred oil and fat components of the skin cosmetic and dermatological agents are the aforementioned mineral and synthetic oils, e.g. Paraffins, silicone oils and aliphatic hydrocarbons having more than 8 carbon atoms, animal and vegetable oils, such as e.g. Sunflower oil, coconut oil, avocado oil, olive oil, lanolin, or waxes, fatty acids, fatty acid esters, e.g. Triglycerides of C6-C30 fatty acids, wax esters, e.g. Jojoba oil, fatty alcohols, vaseline, hydrogenated lanolin and acetylated lanolin, and mixtures thereof.
  • mineral and synthetic oils e.g. Paraffins, silicone oils and aliphatic hydrocarbons having more than 8 carbon atoms
  • animal and vegetable oils such as e.g. Sunflower oil, coconut oil, avocado oil, olive oil, lanolin, or waxes, fatty acids, fatty acid esters, e.g. Triglycerides of C6-C30
  • hydrophobin polypeptide sequences (i) according to the invention can also be mixed with conventional polymers if special properties are to be set.
  • the skin-cosmetic and dermatological preparations can be used. additionally contain conditioning substances based on silicone compounds.
  • Suitable silicone compounds are, for example, polyalkylsiloxanes, polyarylsiloxanes, polyarylalkylsiloxanes, polyethersiloxanes or silicone resins.
  • the preparation of the cosmetic or dermatological preparations is carried out by customary methods known to the person skilled in the art.
  • the cosmetic and dermatological agents are preferably in the form of emulsions, in particular as water-in-oil (W / O) or oil-in-water (O / W) emulsions.
  • formulations for example hydrolispersions, gels, oils, oleogels, multiple emulsions, for example in the form of W / O / W or O / W / O emulsions, anhydrous ointments or ointment bases, etc.
  • Emulsions are prepared by known methods.
  • the emulsions contain, in addition to at least one hydrophobin polypeptide sequence (i), as a rule, customary constituents, such as fatty alcohols, fatty acid esters and, in particular, fatty acid triglycerides, fatty acids, lanolin and derivatives thereof, natural or synthetic oils or waxes and emulsifiers in the presence of water.
  • customary constituents such as fatty alcohols, fatty acid esters and, in particular, fatty acid triglycerides, fatty acids, lanolin and derivatives thereof, natural or synthetic oils or waxes and emulsifiers in the presence of water.
  • a suitable emulsion e.g. for a skin cream, etc.
  • a suitable emulsion generally contains an aqueous phase which is emulsified by means of a suitable emulsifier system in an oil or fat phase.
  • a polyelectrolyte complex can be used.
  • Preferred fat components which may be included in the fat phase of the emulsions are: hydrocarbon oils such as paraffin oil, purcellin oil, perhydrosqualene and solutions of microcrystalline waxes in these oils; animal or vegetable oils, such as sweet almond oil, avocado oil, calophilum oil, lanolin and derivatives thereof, castor oil, seed oil, olive oil, jojoba oil, karite oil, hoplostethus oil, mineral oils whose distillation begins under atmospheric pressure at about 250.degree distillation end at 410 ° C, such as Vaselineöl, esters of saturated or unsaturated fatty acids, such as alkyl myristates, for example i-propyl, butyl or Cetylmyristat, hexadecyl, ethylene or i-propyl palmitate, octanoic or Decankladriglyceride and Cetylricinoleat.
  • hydrocarbon oils such as paraffin oil, purcellin oil, perhydrosqualen
  • the fat phase may also contain other oil-soluble silicone oils, such as dimethylpolysiloxane, methylphenylpolysiloxane and the silicone glycol copolymer, fatty acids and fatty alcohols.
  • oil-soluble silicone oils such as dimethylpolysiloxane, methylphenylpolysiloxane and the silicone glycol copolymer, fatty acids and fatty alcohols.
  • waxes may also be used, e.g. Carnauba wax, candililla wax, beeswax, microcrystalline wax, ozokerite wax and Ca, Mg and Al oleates, myristates, linoleates and stearates.
  • an emulsion of the invention may be present as O / W emulsion.
  • Such an emulsion usually contains an oil phase, emulsifiers which stabilize the oil phase in the water phase, and an aqueous phase, which is usually thickened.
  • Suitable emulsifiers are preferably O / W emulsifiers, such as polyglycerol esters, sorbitan esters or partially esterified glycerides into consideration.
  • the agents according to the invention are a shower gel, a shampoo formulation or a bathing preparation.
  • Such formulations contain at least one hydrophobin polypeptide sequence (i) as well as usually anionic surfactants as base surfactants and amphoteric and / or nonionic surfactants as cosurfactants.
  • suitable active ingredients and / or adjuvants are generally selected from lipids, perfume oils, dyes, organic acids, preservatives and antioxidants and thickeners / gelling agents, skin conditioners and moisturizers.
  • formulations preferably contain from 2 to 50% by weight, preferably from 5 to 40% by weight, particularly preferably from 8 to 30% by weight of surfactants, based on the total weight of the formulation.
  • anionic surfactants are, for example, alkyl sulfates, alkyl ether sulfates, alkyl sulfonates, alkylaryl sulfonates, alkyl succinates, alkyl sulfosuccinates, N-alkoxy sarcosinates, acyl taurates, acyl isothionates, alkyl phosphates, alkyl ether phosphates, alkyl ether carboxylates, alpha-olefin sulfonates, in particular the alkali metal and alkaline earth metal salts, for example sodium, potassium , Magnesium, calcium, as well as ammonium and triethanolamine salts.
  • alkali metal and alkaline earth metal salts for example sodium, potassium , Magnesium, calcium, as well as ammonium and triethanolamine salts.
  • the alkyl ether sulfates, alkyl ether phosphates and alkyl ether carboxylates can have between 1 to 10 ethylene oxide or propylene oxide units, preferably 1 to 3 ethylene oxide units in the molecule. These include, for example, sodium lauryl sulfate, ammonium tauryl sulfate, sodium lauryl ether sulfate, ammonium lauryl ether sulfate, sodium lauryl sarcosinate, sodium oleyl succinate, ammonium lauryl sulfosuccinate, sodium dodecylbenzenesulfonate and triethanolamine dodecylbenzene sulfonate.
  • Suitable amphoteric surfactants are e.g. Alkylbetaines, alkylamidopropylbetaines, alkylsulfobetaines, alkylglycinates, alkylcarboxyglycinates, alkylamphoacetates or -propionates, alkylamphodiacetates or -dipropionates.
  • cocodimethylsulfopropyl betaine cocodimethylsulfopropyl betaine, lauryl betaine, cocamidopropyl betaine or sodium cocamphopropionate can be used.
  • Suitable nonionic surfactants are, for example, the reaction products of aliphatic alcohols or alkylphenols having 6 to 20 C atoms in the alkyl chain, which may be linear or branched, with ethylene oxide and / or propylene oxide.
  • the amount of alkylene oxide is about 6 to 60 moles per mole of alcohol.
  • alkylamine oxides, mono- or dialkylalkanolamides, fatty acid esters of polyethylene glycols, ethoxylated fatty acid amides, alkylpolyglycosides or sorbitan ether esters are also suitable.
  • washing, showering and bathing preparations may contain conventional cationic surfactants, such as e.g. quaternary ammonium compounds, for example cetyltrimethylammonium chloride.
  • conventional cationic surfactants such as e.g. quaternary ammonium compounds, for example cetyltrimethylammonium chloride.
  • shower gel / shampoo formulations thickeners such as sodium chloride, PEG-55 propylene glycol oleate, PEG-120 methylglucose dioleate and others, so-as preservatives, other active 'and auxiliaries and water.
  • the invention appropriate means to a hair treatment agent.
  • Hair treatment agents according to the invention preferably contain at least one hydrophobin polypeptide sequence (i) in an amount in the range of about 0.000001 to 10% by weight, preferably 0.00001 to 1% by weight, based on the total weight of the composition.
  • the hair treatment compositions of the present invention are in the form of a mousse, hair mousse, hair gel, shampoo, hair spray, hair mousse, top fluid, perming, hair dyeing and bleaching or hot oil treatments.
  • the hair cosmetic preparations can be applied as (aerosol) spray, (aerosol) foam, gel, gel spray, cream, lotion or wax.
  • Hairsprays include both aerosol sprays and pump sprays without propellant gas.
  • Hair foams include both aerosol foams and pump foams without propellant gas.
  • Hair sprays and hair foams preferably comprise predominantly or exclusively water-soluble or water-dispersible components.
  • the compounds used in the hair sprays and hair foams according to the invention are water-dispersible, they can be used in the form of aqueous microdispersions with particle diameters of usually from 1 to 350 nm, preferably from 1 to 250 nm.
  • the solids contents of these preparations are usually in a range of about 0.5 to 20 wt .-%.
  • these microdispersions do not require emulsifiers or surfactants for their stabilization.
  • the hair cosmetic formulations according to the invention contain in a preferred embodiment a) 0.000001 to 10% by weight of at least one hydrophobin polypeptide sequence (i), b) 20 to 99.95% by weight of water and / or alcohol, c) 0 to 50% by weight of at least one propellant, d) 0 to 5% by weight of at least one emulsifier, e) 0 to 3% by weight of at least one thickener and up to 25% by weight of further constituents.
  • alcohol By alcohol are meant all alcohols customary in cosmetics, e.g. Ethanol, isopropanol, n-propanol.
  • Further constituents are understood to mean the additives customary in cosmetics, for example propellants, defoamers, surface-active compounds, ie surfactants, emulsifiers, foaming agents and solubilizers.
  • the interface used active compounds may be anionic, cationic, amphoteric or neutral.
  • Further customary constituents may also be, for example, preservatives, perfume oils, opacifiers, active ingredients, UV filters, care substances such as panthenol, collagen, vitamins, protein hydrolysates, alpha- and beta-hydroxycarboxylic acids, stabilizers, pH regulators, dyes, viscosity regulators, gel formers, Salts, humectants, greases, complexing agents and other common additives.
  • this includes all known in cosmetics styling and conditioner polymers, which can be used in combination with the hydrophobin polypeptide sequences (i) according to the invention, if very special properties are to be set.
  • Suitable conventional hair cosmetic polymers are, for example, the abovementioned cationic, anionic, neutral, nonionic and amphoteric polymers, to which reference is made here.
  • the preparations may additionally contain conditioning substances based on silicone compounds.
  • Suitable silicone compounds are, for example, polyalkylsiloxanes, polyarylsiloxanes, polyarylalkylsiloxanes, polyethersiloxanes, silicone resins or dimethicone copolyols (CTFA) and amino-functional silicone compounds such as amodimethicones (CTFA).
  • the polymers according to the invention are suitable in particular as setting agents in hairstyling preparations, in particular hairsprays (aerosol sprays and pump sprays without propellant gas) and hair foams (aerosol foams and pump foams without propellant gas).
  • spray formulations contain a) 0.000001 to 10% by weight of at least one hydrophobin polypeptide sequence (i), b) 90 to 99.9% by weight of water and / or alcohol, c) 0 to 70 Wt .-% of at least one blowing agent, d) 0 to 20 wt .-% further ingredients.
  • Blowing agents are the blowing agents commonly used for hairsprays or aerosol foams. Preference is given to mixtures of propane / butane, pentane, dimethyl ether, 1,1-difluoroethane (HFC-152a), carbon dioxide, nitrogen or compressed air.
  • a preferred formulation for aerosol hair foams according to the invention contains a) 0.000001 to 10% by weight of at least one hydrophobin polypeptide sequence (i), b) 90 to 99.9% by weight of water and / or alcohol, c) 5 to 20% by weight of a propellant, d) 0 , 1 to 5 wt .-% of an emulsifier, e) 0 to 10 wt .-% further constituents.
  • emulsifiers all emulsifiers commonly used in hair foams can be used. Suitable emulsifiers may be nonionic, cationic or anionic or amphoteric.
  • nonionic emulsifiers are Laurethe, e.g. Laureth-4; Cetethe, e.g. Cetheth-1, polyethylene glycol cetyl ether, ceteareth, e.g. Cethetereth-25, polyglycol fatty acid glycerides, hydroxylated lecithin, lactyl esters of fatty acids, alkylpolyglycosides.
  • cationic emulsifiers are cetyldimethyl-2-hydroxyethylammonium dihydrogenphosphate, cetyltrimonium chloride, cetyltrimmonium bromide, cocotrimonium methylsulfate, quaternium-1 to x (INCI).
  • Anionic emulsifiers may, for example, be selected from the group of alkyl sulfates, alkyl ether sulfates, alkyl sulfonates, alkylaryl sulfonates, alkyl succinates, alkyl sulfosuccinates, N-alkoyl sarcosinates, acyl taurates, acyl isethionates, alkyl phosphates, alkyl ether phosphates, alkyl ether carboxylates, alpha olefin sulfonates, especially the alkali and alkaline earth metal salts, e.g.
  • alkyl ether sulfates, alkyl ether phosphates and alkyl ether carboxylates can have between 1 to 10 ethylene oxide or propylene oxide units, preferably 1 to 3 ethylene oxide units in the molecule.
  • a preparation suitable for styling gels according to the invention can be composed, for example, as follows: a) 0.000001 to 10% by weight of at least one hydrophobin polypeptide sequence (i), b) 80 to 99.85% by weight of water and / or Alcohol, c) 0 to 3 wt .-%, preferably 0.05 to 2 wt .-%, of a gelling agent, d) 0 to 20 wt .-% further ingredients.
  • hydrophobin polypeptide sequences (i) used according to the invention are already “self-thickening", so that in many cases the use of gelling agents can be dispensed with in the preparation of gels. Their use, however, may be advantageous to adjust for specific rheological or other performance properties of the gels.
  • gel formers all in the cosmetics commonly used gel former.
  • polyacrylic acid for example carbomer (INCI)
  • cellulose derivatives for example hydroxypropylcellulose, hydroxyethylcellulose, cationically modified celluloses
  • polysaccharides for example xanthan gum, caprylic / capric triglyceride, sodium acrylate copolymers
  • polyquaternium-32 and) paraffin liquid (INCI)
  • Sodium acrylate copolymers and) Paraffin Liquidum (and) PPG-1 trideceth-6, acrylamidopropyltrimonium chloride / acrylamide copolymers, steareth-10-allyl ethers, acrylate copolymers
  • hydrophobin polypeptide sequences (i) according to the invention can be used as conditioners in cosmetic preparations.
  • a formulation containing the hydrophobin polypeptide sequences (i) according to the invention can preferably be used in shampoo formulations as a setting and / or conditioning agent.
  • Preferred shampoo formulations comprise a) 0.000001 to 10% by weight of at least one hydrophobin polypeptide sequence (i), b) 25 to 94.95% by weight of water, c) 5 to 50% by weight of surfactants, c) 0 to 5% by weight of a further conditioning agent, d) 0 to 10% by weight of further cosmetic constituents.
  • Suitable anionic surfactants are, for example, alkyl sulfates, alkyl ether sulfates, alkyl sulfonates, alkyl aryl sulfonates, alkyl succinates, alkyl sulfosuccinates,
  • the alkyl ether sulfates, alkyl ether phosphates and alkyl ether carboxylates can have between 1 to 10 ethylene oxide or propylene oxide units, preferably 1 to 3 ethylene oxide units in the molecule.
  • Suitable examples are sodium lauryl sulfate, ammonium lauryl sulfate, sodium lauryl ether sulfate, ammonium lauryl ether sulfate, sodium lauroyl sarcosinate, sodium oleyl succinate, ammonium lauryl sulfosuccinate, sodium dodecylbenzenesulfonate and triethanolamine dodecylbenzenesulfonate.
  • Suitable amphoteric surfactants are, for example, alkylbetaines, alkylamidopropylbetaines, alkylsulfobetaines, alkylglycinates, alkylcarboxyglycinates, alkylamphoacetates or -propionates, alkylamphodiacetates or -dipropionates.
  • cocodimethylsulfopropyl betaine cocodimethylsulfopropyl betaine, lauryl betaine, cocamidopropyl betaine or sodium cocamphopropionate can be used.
  • nonionic surfactants are the reaction products of aliphatic alcohols or alkylphenols having 6 to 20 C atoms in the alkyl chain, which may be linear or branched, with ethylene oxide and / or propylene oxide.
  • the amount of alkylene oxide is about 6 to 60 moles per mole of alcohol.
  • alkylamine oxides, mono- or dialkylalkanolamides, fatty acid esters of polyethylene glycols, alkylpolyglycosides or sorbitan ether esters are also suitable.
  • the shampoo formulations may contain conventional cationic surfactants, e.g. quaternary ammonium compounds, for example cetyltrimethylammonium chloride.
  • conventional cationic surfactants e.g. quaternary ammonium compounds, for example cetyltrimethylammonium chloride.
  • Conventional conditioning agents in combination with the hydrophobin polypeptide sequences (i) can be used in the shampoo formulations to achieve certain effects.
  • cationic polymers with the name Polyquaternium according to INCI, in particular copolymers of vinylpyrrolidone / N-vinylimidazolium salts (Luviquat FC, Luviquat & commat, HM, Luviquat MS, Luviquat Care), copolymers of N-vinylpyrrolidone / dimethylaminoethyl methacrylate, quaternized with diethyl sulfate ( Luviquat D PQ 11), copolymers of N-vinylcaprolactam / N-vinylpyrrolidone / N-vinylimidazolium salts (Luviquat D Hold), cationic cellulose derivatives (Polyquaternium-4 and -10), acrylamide copolymers (Polyquaternium-7).
  • protein hydrolysates can be used, as well as conditioning substances based on silicone compounds, for example polyalkylsiloxanes, polyarylsiloxanes, polyarylalkylsiloxanes, polyethersiloxanes or silicone resins.
  • silicone compounds for example polyalkylsiloxanes, polyarylsiloxanes, polyarylalkylsiloxanes, polyethersiloxanes or silicone resins.
  • suitable silicone compounds are dimethicone copolyols (CTFA) and amino-functional silicone compounds such as amodimethicones (CTFA).
  • CTFA dimethicone copolyols
  • amino-functional silicone compounds such as amodimethicones
  • cationic guar derivatives such as guar hydroxypropyltrimonium chloride (INCI) can be used.
  • this hair cosmetic or skin cosmetic preparation is for the care or protection of the skin or hair and is in the form of an emulsion, a dispersion, a suspension, an aqueous surfactant preparation, a milk, a lotion, a cream, a balm, an ointment, gel, granule, powder, stick preparation, such as a lipstick, foam, aerosol or spray.
  • emulsions are oil-in-water emulsions and water-in-oil emulsions or microemulsions.
  • the hair cosmetic or skin cosmetic preparation is used for application on the skin (topically) or hair.
  • Topical preparations are to be understood as meaning those preparations which are suitable for applying the active ingredients to the skin in fine distribution and preferably in a form absorbable by the skin.
  • aqueous and aqueous-alcoholic solutions sprays, foams, foam aerosols, ointments, aqueous gels, emulsions of the O / W or W / O type, microemulsions or cosmetic stick preparations.
  • the agent contains a carrier.
  • a carrier is water, a gas, a water-based liquid, an oil, a gel, an emulsion or a microemulsion, a dispersion or a mixture thereof.
  • the mentioned carriers show good skin tolerance.
  • Particularly advantageous for topical preparations are aqueous gels, emulsions or microemulsions.
  • Nonionic surfactants, zwitterionic surfactants, ampholytic surfactants or anionic emulsifiers can be used as emulsifiers.
  • the emulsifiers may be present in the composition according to the invention in amounts of 0.1 to 10, preferably 1 to 5 wt .-%, based on the composition.
  • a surfactant of at least one of the following groups may be used:
  • Alkyl mono- and oligoglycosides having 8 to 22 carbon atoms in the alkyl radical and their ethoxylated analogs
  • Polyol and especially polyglycerol esters e.g. Polyglycerinpolyricinoleat, Polygl ycerinpoly-12-hydroxystearat or Polyglycerindimerat. Also suitable are mixtures of compounds of several of these classes of substances;
  • Partial esters based on linear, branched, unsaturated or saturated C 6/22 fatty acids, ricinoleic acid and 12-hydroxystearic acid and glycerol, polyglycerol, pentaerythritol, dipentaerythritol, sugar alcohols (eg sorbitol), alkyl glucosides (eg methyl glucoside, Butyl glucoside, lauryl glucoside) as well as polyglucosides (eg cellulose);
  • zwitterionic surfactants can be used as emulsifiers.
  • Zwitterionic surfactants are surface-active compounds which have at least one quaternary ammonium group and at least one carbene in the molecule. carry boxylate or a sulfonate group.
  • Particularly suitable zwitterionic surfactants are the so-called betaines, such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylamino-propyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and Alkyl-3-carboxylmethyl-3-hydroxyethylimidazolines having in each case 8 to 18 carbon atoms in the alkyl or acyl group and the Kokosacylaminoethylhydro- xyethyl-carboxymethylglycinat.
  • Particularly preferred is the known under the CTFA name Cocamidopropyl Betaine fatty acid amide derivative.
  • ampholytic surfactants are surface-active compounds which, apart from a C 8, i 8 alkyl or acyl group in the molecule at least one free amino group and at least one -COOH or -S0 3 H group and are capable of forming inner salts .
  • suitable ampholytic surfactants are N-alkylglycines, N-alkylpropionic acids, N-alkylamino-butanoic acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamido-propylglycines, N-alkyltaurines, N alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 18 C atoms in the alkyl group.
  • ampholytic surfactants are N-cocoalkylaminopropionate, cocoacylaminoethyl aminopropionate and C i 2 / i 8 acyl sarcosine.
  • quaternary emulsifiers are also suitable, with those of the esterquat type, preferably methyl-quaternized difatty acid triethanolamine ester salts, being particularly preferred. It is also possible to use, as anionic emulsifiers, alkyl ether sulfates, monoglyceride sulfates, fatty acid sulfates, sulfosuccinates and / or ether carboxylic acids.
  • Suitable oil components are Guerbet alcohols based on fatty alcohols having 6 to 18, preferably 8 to 10 carbon atoms, esters of linear C 6 -C 22 fatty acids with linear C 6 -C 22 -Fettaikohoien, esters of branched C 6 -C 3 - Carboxylic acids with linear C 6 - C 22 -FeUaI koholen, esters of linear C 6 -C 22 fatty acids with branched alcohols, especially 2-ethylhexanol, esters of linear and / or branched fatty acids with polyhydric alcohols (such as propylene glycol, dimerdiol or trimer triol ) and / or Guerbet alcohols, triglycerides based on C 6 -C 10 -fatty acids, liquid mono- / di-, triglyceride mixtures based on C 6 -C 8 -fatty acids, esters of C 6 -C 22 -fatty alcohols and /
  • silicone oil compounds are silicone compounds, for example dimethylpolysiloxanes, methylphenylpolysiloxanes, cyclic silicones and also amino, fatty acid, alcohol, polyether, epoxy, fluorine, alkyl and / or glycoside-modified silicone compounds which may be both liquid and resinous at room temperature.
  • the oil particles may be present in the compositions according to the invention in amounts of from 1 to 90, preferably from 5 to 80, and in particular from 10 to 50,% by weight, based on the composition.
  • the duration of action on the skin can be significantly prolonged.
  • the coupling takes place as described above, formulation and application are carried out by methods known to the person skilled in the art.
  • Particularly suitable for deodorants are suitable effector molecules (ii): perfume oils, cyclodextrins, ion exchangers, zinc ricinoleate, germ-inhibiting / bacteriostatic compounds (for example DCMX, Irgasan DP 300, TCC).
  • Suitable antiperspirants are: tannins, and zinc / aluminum salts.
  • Another field of application for the substances according to the invention is the therapeutic or prophylactic use in certain diseases of the skin and mucous membranes.
  • viral diseases e.g., herpes, coxsackie, varicella zoster, cytomegalovirus, etc.
  • bacterial diseases e.g., TB, syphilis, etc.
  • fungal diseases e.g., Candida, Cryptococcus, Histoplasmosis, Aspergillus,
  • Mucormycosis, etc. - tumors (e.g., melanomas, adenomas, etc.)
  • Autoimmune diseases e.g., PEMPHIGUS VULGARIS, BULLOUS PEMPHIGOID, SYSTEMIC LUPUS ERYTHEMATOSA, etc.
  • Sunburn parasitic infestation eg ticks, mites, fleas etc.
  • insect contact eg blood-sucking insects such as Anopheles etc.
  • the substances suitable for therapy or prophylaxis eg corticoids, immunosuppressive compounds, antibiotics, antimycotics, anti-viral compounds, insect repellent, etc.
  • Keratin-binding polypeptides i) are coupled.
  • oligonucleotides Hal570 and Hal571 (HaI 572 / HaI 573) a polymerase chain reaction was carried out.
  • the PCR fragment obtained contained the coding sequence of the gene yaaD / yaaE from Bacillus subtilis, and at the ends in each case an NcoI or BglII restriction cleavage site.
  • the PCR fragment was purified and cut with the restriction endonucleases NcoI and BglII.
  • This DNA fragment was used as insert, and cloned into the vector pQE60 from Qiagen, previously linearized with the restriction endonucleases NcoI and BglI.
  • the resulting vectors pQE60YAAD # 2 / pQE60YaaE # 5 can be used to express proteins consisting of, YAAD :: HIS 6 and YAAE :: HIS 6
  • Hal570 gcgcgcccatggctcaaacaggtactga
  • Hal571 gcagatctccagccgcgttcttgcatac
  • Hal572 ggccatgggattaacaataggtgtactagg
  • Hal573 gcagatcttacaagtgccttttgcttatattcc
  • the oligonucleotides KaM 416 and KaM 417 Using the oligonucleotides KaM 416 and KaM 417, a polymerase chain reaction was carried out.
  • the template DNA used was genomic DNA of the mold Aspergillus nidulans.
  • the resulting PCR fragment contained the coding sequence of the hydrophobin gene dewA and an N-terminal factor Xa proteinase cleavage site.
  • the PCR fragment was purified and cut with the restriction endonuclease Barn HI. This DNA fragment was used as insect, and in the previously linearized with the restriction endonuclease BgIII vector pQE60YAAD # 2 cloned.
  • the resulting vector # 508 can be used to express a fusion protein consisting of, YAAD :: Xa :: dewA :: HIS 6 .
  • KaM416 GCAGCCCATCAGGGATCCCTCAGCCTTGGTACCAGCGC
  • KaM417 CCCGTAGCTAGTGGATCCATTGAAGGCCGCATGAAGTTCTCCGTCTCCGC
  • plasmid # 513 The cloning of plasmid # 513 was carried out analogously to plasmid # 508 using the oligonucleotides KaM 434 and KaM 435.
  • KaM434 GCTAAGCGGATCCATTGAAGGCCGCATGAAGTTCTCCATTGCTGC KaM435: CCAATGGGGATCCGAGGATGGAGCCAAGGG
  • the cloning of plasmid # 507 was carried out analogously to plasmid # 508 using the oligonucleotides KaM 417 and KaM 418.
  • the template DNA used was an artificially synthesized DNA sequence - hydrophobin BASF1 (see Appendix).
  • KaM417 CCCGTAGCTAGTGGATCCATTGAAGGCCGCATGAAGTTCTCCGTCTCCGC
  • KaM418 CTGCCATTCAGGGGATCCCATATGGAGGAGGGAGACAG
  • plasmid # 506 The cloning of plasmid # 506 was carried out analogously to plasmid # 508 using the oligonucleotides KaM 417 and KaM 418.
  • template DNA an artificially synthesized DNA sequence - hydrophobin BASF2 - was used (see Appendix).
  • KaM417 CCCGTAGCTAGTGGATCCATTGAAGGCCGCATGAAGTTCTCCGTCTCCGC
  • Plasmid # 526 was analogous to plasmid # 508 using the oligonucleotides KaM464 and KaM465.
  • the template DNA used was Schyzophyllum commune cDNA (see Appendix).
  • KaM464 CGTTAAGGATCCGAGGATGTTGATGGGGGTGC
  • KaM465 GCTAACAGATCTATGTTCGCCCGTCTCCCCGTCGT
  • 100 g cell pellet (100-500 mg hydrophobin) are made up to 200 ml total volume with 50 mM sodium phosphate buffer, pH 7.5 and resuspended.
  • the suspension is treated with an Ultraturrax type T25 (Janke and Kunkel, IKA-Labortechnik) for 10 minutes and then incubated for 1 hour at room temperature with 500 units of benzonase (Merck, Darmstadt, Order No. 1.01697.0001) to break down the nucleic acids.
  • filter with a glass cartridge P1.
  • two homogenizer runs are carried out at 1500 bar (Microfluidizer M-110EH, Microfluidics Corp.).
  • the homogenate is centrifuged (Sorvall RC-5B, GSA rotor, 250 ml centrifuge beaker, 60 minutes, 4 ° C, 12,000 rpm, 23,000 g), the supernatant placed on ice and the pellet resuspended in 100 ml sodium phosphate buffer, pH 7.5 , Centrifugation and resuspension are repeated 3 times with the sodium phosphate buffer containing 1% SDS at the third repetition. After resuspension, stir for one hour and carry out a final centrifugation (Sorvall RC-5B, GSA rotor, 250 ml centrifuge beaker, 60 minutes, 4 ° C, 12,000 rpm, 23,000 g).
  • the hydrophobin is contained in the supernatant after the final centrifugation ( Figure 1).
  • the experiments show that the hydrophobin is probably contained in the form of inclusion bodies in the corresponding E. coli cells.
  • 50 ml of the hydrophobin-containing supernatant are applied to a 50 ml nickel-Sepharose High Performance 17-5268-02 column (Amersham) equilibrated with 50 mM Tris-Cl pH 8.0 buffer.
  • the column is washed with 50 mM Tris-Cl pH 8.0 buffer and the hydrophobin is subsequently eluted with 50 mM Tris-Cl pH 8.0 buffer containing 200 mM imidazole.
  • the solution is dialyzed against 50 mM Tris-Cl pH 8.0 buffer.
  • Lane 1 shows the purification of the hydrophobin according to the invention: Lane 1: application of nickel-Sepharose column (1:10 dilution)
  • Lanes 3 - 5 OD 280 maxima of the elution fractions
  • the inventive hydrophobin of Figure 1 has a molecular weight of about 53 kD.
  • the smaller bands partially represent degradation products of the hydrophobin.
  • the samples are air dried and the contact angle (in degrees) of a drop of 5 ⁇ l of water is determined. There are e.g. the following values:
  • the samples are air dried and the contact angle (in degrees) of a drop of 5 ⁇ l of water is determined.
  • the contact angle measurement was performed on a device Dataphysics Contact Angle System OCA 15+, Software SCA 20.2.0. (November 2002). The measurement was carried out according to the manufacturer's instructions.
  • TBS 2OmM Tris; 15 mM NaClpH 7.5
  • TTBS TBS + 0.05% Tween20
  • the first step is the transfer of the outer keratin layer from the skin to a stable carrier.
  • a transparent adhesive strip was firmly applied to depilated human skin and removed again.
  • the test can be carried out directly on the transparent adhesive strip or the adhering keratin layer can be transferred to a glass slide by re-adhering.
  • the binding was detected as follows: for incubation with the various reagents, transfer into a Falcon vessel, if necessary addition of ethanol for degreasing, removal of ethanol and drying of the slides
  • the amount of absorption indicates the amount of bound hydrophobin or control protein.
  • comparative protein e.g. YaaD from B. subtilis, which also had a His tag for detection as needed for this test.
  • His tag instead of the His tag, other specific antibodies conjugated to peroxidase may also be used.
  • BSA bovine serum albumin
  • PBS phosphate buffered saline
  • Tween 20 polyoxyethylene sorbitan monolaureate
  • TMB 3,5,3, 1 O 1 tetramethylbenzidine
  • hydrophobin-based binding test on hair showed a clear superiority of the binding of hydrophobin to hair compared to a substantially poorer binding of the control protein YaaD:
  • Table 1 Quantitative Hydrophobin Activity Test Hair: 1) Buffer; 2) comparative protein yaad; 3) hydrophobin.
  • the table shows the measured absorbance values at 405 nm.
  • Analogous to Example 11 (binding to the skin) the binding to the mucous membrane can also be measured by taking a sample of mucous membrane (for example human oral mucosa) by means of a transparent adhesive strip, which can then be examined for binding action.
  • the binding to teeth can be determined by incubating the polypeptide sequences to be examined directly with the tooth surface (for example bovine teeth) and measuring according to Example 11.
  • the coupling of the dye is carried out according to the manufacturer's instructions (Alexa 532 Protein Delivery Kit, Molecular Probes, MP-A-10236).
  • the coating of human hair with Alexa-coupled hydrophobin is performed as follows:
  • Preparation Heat phases A and B separately from each other to about 80 ° C. Stir phase B into phase A and homogenize. Incorporate phase C into the combined phases A and B and homogenize. Cool with stirring to about 40 ° C. Add phase D, adjust the pH to about 6.5 with phase E and homogenize. Cool to room temperature while stirring.
  • hydrophobin in a facial cleansing lotion - Type O / W
  • Preparation Mix the components of phase A. Dissolve phase B, work in phase A and homogenize.
  • Preparation Heat the components of phases A and B separately from each other to approx. 80 ° C. Stir phase B into phase A and homogenize. Heat phase C to about 80 ° C. and stir into the combined phases A and B while homogenizing. Cool with stirring to about 40 0 C, add phase D and homogenize again.
  • hydrophobin in a sunscreen lotion - Type O / W
  • Preparation Heat the components of phases A and B separately from each other to approx. 80 ° C. Stir phase B into phase A while homogenizing. Cool with stirring to about 40 0 C, add the phases C and D and briefly nachhomogen gives. Cool to room temperature while stirring.
  • Example 26 Use of the hydrophobin in a W / O emulsion with bisabolol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition cosmétique destinée au traitement de substances contenant de la kératine, de muqueuses et de dents, laquelle composition contient au moins une séquence polypeptidique d'hydrophobine (i) Xn-C1-X1-50-C2-X0-5-C3-Xp-C4-X1-100-C5-X1-50-C6-X0-5-C7-X1-50-C8-Xm (I)
EP06777430A 2005-06-24 2006-06-23 Utilisation de polypeptides d'hydrophobine et de conjugues de polypeptides d'hydrophobine avec des substances actives ou a effet ainsi que leur production et leur application en cosmetique Withdrawn EP1898871A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005029704A DE102005029704A1 (de) 2005-06-24 2005-06-24 Verwendung von Hydrophobin-Polypeptiden sowie Konjugaten aus Hydrophobin-Polypeptiden mit Wirk-oder Effektstoffen und ihre Herstellung sowie deren Einsatz in der Kosmetik
PCT/EP2006/063485 WO2006136607A2 (fr) 2005-06-24 2006-06-23 Utilisation de polypeptides d'hydrophobine et de conjugues de polypeptides d'hydrophobine avec des substances actives ou a effet ainsi que leur production et leur application en cosmetique

Publications (1)

Publication Number Publication Date
EP1898871A2 true EP1898871A2 (fr) 2008-03-19

Family

ID=37562328

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06777430A Withdrawn EP1898871A2 (fr) 2005-06-24 2006-06-23 Utilisation de polypeptides d'hydrophobine et de conjugues de polypeptides d'hydrophobine avec des substances actives ou a effet ainsi que leur production et leur application en cosmetique

Country Status (7)

Country Link
US (1) US20090136433A1 (fr)
EP (1) EP1898871A2 (fr)
JP (2) JP5452916B2 (fr)
CN (1) CN101203207B (fr)
CA (1) CA2612458C (fr)
DE (1) DE102005029704A1 (fr)
WO (1) WO2006136607A2 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220405B2 (en) 2003-09-08 2007-05-22 E. I. Du Pont De Nemours And Company Peptide-based conditioners and colorants for hair, skin, and nails
US7585495B2 (en) 2003-09-08 2009-09-08 E. I. Du Pont De Nemours And Company Method for identifying shampoo-resistant hair-binding peptides and hair benefit agents therefrom
US7807141B2 (en) 2003-09-08 2010-10-05 E.I. Du Pont De Nemours And Company Peptide-based oral care surface reagents for personal care
JP5250264B2 (ja) * 2005-02-07 2013-07-31 ビーエーエスエフ ソシエタス・ヨーロピア 新規ハイドロフォビン融合タンパク質、その製造および使用
BRPI0607594A2 (pt) 2005-03-31 2010-04-06 Basf Ag compósito multi-camadas ou substrato revestido, processo para a preparação dos mesmos, e, uso de hidrofobinas
JP2008534554A (ja) 2005-04-01 2008-08-28 ビーエーエスエフ ソシエタス・ヨーロピア 乳化破壊剤としての蛋白質の使用
CN101228249B (zh) 2005-04-01 2011-11-30 巴斯福股份公司 含疏水蛋白的钻井液
DE102005027139A1 (de) 2005-06-10 2006-12-28 Basf Ag Neue Cystein-verarmte Hydrophobinfusionsproteine, deren Herstellung und Verwendung
DE102005029704A1 (de) * 2005-06-24 2007-01-11 Basf Ag Verwendung von Hydrophobin-Polypeptiden sowie Konjugaten aus Hydrophobin-Polypeptiden mit Wirk-oder Effektstoffen und ihre Herstellung sowie deren Einsatz in der Kosmetik
DE102005033002A1 (de) * 2005-07-14 2007-01-18 Basf Ag Wässrige Monomeremulsionen enthaltend Hydrophobin
DE602006004369D1 (de) * 2005-09-23 2009-01-29 Unilever Nv Durchlüftete produkte mit niedrigem ph-wert
ZA200800988B (en) * 2005-09-23 2009-08-26 Unilever Plc Aerated products with reduced creaming
CA2616282C (fr) * 2005-09-23 2014-02-04 Unilever Plc Procede de production d'une composition aeree congelee
DE102005048720A1 (de) 2005-10-12 2007-04-19 Basf Ag Verwendung von Proteinen als Antischaum-Komponente in Kraftstoffen
AU2006344932A1 (en) * 2005-11-24 2007-12-27 Basf Se Keratin-binding effector molecules, and method for the production thereof
WO2007060116A2 (fr) * 2005-11-24 2007-05-31 Basf Se Procede pour coupler des polypeptides se liant a la keratine, a des molecules effectrices portant des groupes carboxyle ou des groupes acide sulfonique
US20090098074A1 (en) * 2005-12-01 2009-04-16 Basf Se Keratin-Binding Effector Molecules Containing Reactive Dyes
ES2374320T3 (es) * 2006-08-15 2012-02-15 Basf Se Procedimiento para la producción de preparaciones de hidrofobina secas de flujo libre.
BRPI0705417B1 (pt) * 2006-12-20 2016-08-16 Unilever Nv produto alimentício aerado e processos para a produção de um produto alimentício aerado
FR2915101B1 (fr) * 2007-04-23 2011-07-29 Fabre Pierre Dermo Cosmetique Composition dermatologique pour la prevention et/ou le traitement de la rosacee, de la couperose ou des peaux qui presentent des rougeurs diffuses ou des petits vaisseaux dilates
CA2698293A1 (fr) * 2007-09-13 2009-03-26 Thomas Subkowski Utilisation de polypeptides de type hydrophobine comme renforcateurs de penetration
EP2042155A1 (fr) * 2007-09-28 2009-04-01 Basf Se Procédé de suppression de substances indissolubles dans l'eau de surfaces de substrat
JP4990733B2 (ja) * 2007-10-04 2012-08-01 花王株式会社 透明液状化粧料
WO2009050222A1 (fr) * 2007-10-18 2009-04-23 Unilever Plc Procédé de production d'un agent moussant
WO2009112301A2 (fr) * 2008-03-10 2009-09-17 Basf Se Agents actifs polypeptidiques sous la forme de conjugués de polypeptides liant la kératine, de polymères, et de molécules effectrices, procédés pour leur élaboration, et leur utilisation
JP2012500241A (ja) * 2008-08-18 2012-01-05 ビーエーエスエフ ソシエタス・ヨーロピア ケラチンの非永久的染色のためのハイドロフォビンの使用
CN102186967B (zh) * 2008-10-16 2015-11-25 荷兰联合利华有限公司 包含消泡剂的疏水蛋白溶液
EP2342237B1 (fr) * 2008-11-03 2014-04-23 Basf Se Mélanges de photo-initiateurs
US8226967B2 (en) 2008-11-27 2012-07-24 Basf Se Surface active proteins as excipients in solid pharmaceutical formulations
BRPI0916501A2 (pt) 2008-12-16 2015-11-10 Unilever Nv processo para extrair hidrofobina de uma solução
US8287845B2 (en) * 2008-12-18 2012-10-16 E I Du Pont De Nemours And Company Hair-binding peptides
US20100158846A1 (en) * 2008-12-18 2010-06-24 E. I. Du Pont De Nemours And Company Hair-binding peptides
US20100158822A1 (en) * 2008-12-18 2010-06-24 E .I. Du Pont De Nemours And Company Peptides that bind to silica-coated particles
US20110312497A1 (en) * 2009-02-10 2011-12-22 Basf Se Use of hydrophobin as a spreading agent
CN102333546B (zh) * 2009-02-26 2014-11-26 Brain生物技术研究与信息网络股份公司 用于在跨角蛋白的局部药物递送中使用表面活性蛋白的组合物、用途和方法
JP2012519767A (ja) * 2009-03-09 2012-08-30 ビーエーエスエフ ソシエタス・ヨーロピア 水相増粘用の水溶性ポリマーとハイドロフォビンの相乗性混合物の利用
WO2010114638A1 (fr) 2009-03-30 2010-10-07 E. I. Du Pont De Nemours And Company Réactifs à base de peptides pour blanchissement des dents
US8357420B2 (en) * 2009-05-29 2013-01-22 Conopco, Inc. Oil-in-water emulsion
US8394444B2 (en) * 2009-05-29 2013-03-12 Conopco, Inc. Oil-in-water emulsion
CA2704702C (fr) * 2009-06-02 2018-06-12 Unilever Plc Produits aeres cuits au four
FI20095638A0 (fi) * 2009-06-09 2009-06-09 Valtion Teknillinen Hydrofobiineja aktiivisten aineiden dispergointiin
US20120128858A1 (en) * 2009-06-18 2012-05-24 Deborah Lynne Aldred Water-in-oil emulsion with improved spattering behaviour
EP2462166A2 (fr) * 2009-08-03 2012-06-13 Basf Se Procédé pour le dépôt de couches minces d'oxydes métalliques
EP2371844A1 (fr) 2010-03-25 2011-10-05 B.R.A.I.N. Biotechnology Research and Information Network AG Protéines actives à surface chimérique
WO2011101457A1 (fr) 2010-02-18 2011-08-25 B.R.A.I.N. Biotechnology Research And Information Network Ag Protéines tensioactives chimères
MX2012014447A (es) * 2010-06-17 2013-02-07 Unilever Nv Composiciones para el cuidado oral.
US20130202539A1 (en) * 2010-08-12 2013-08-08 Eleanor Margaret D'Agostino Oral care compositions
EA201390260A1 (ru) 2010-08-20 2013-06-28 Унилевер Н.В. Композиция для ухода за волосами
WO2012049250A2 (fr) * 2010-10-13 2012-04-19 Basf Se Procédé pour immobiliser des principes actifs cationiques sur des surfaces
DE102010063942B4 (de) * 2010-12-22 2015-03-26 Technische Universität Dresden Verfahren und Verwendung von Hydrophobinen zur Herabsetzung der Oberflächenspannung in Zellkulturen
RU2013150782A (ru) * 2011-04-15 2015-05-20 ДАНИСКО ЮЭс ИНК. Способы очистки гидрофобина
EP3031444B1 (fr) 2011-08-02 2018-10-10 Shiseido Company, Ltd. Produit cosmétique en émulsion de type huile dans eau
ITTO20111094A1 (it) * 2011-11-28 2013-05-29 Fond Istituto Italiano Di Tecnologia Proteina fluorurata e suoi impieghi.
WO2013113451A2 (fr) 2012-01-31 2013-08-08 Unilever Plc Composition de soins personnels
WO2013113556A2 (fr) * 2012-01-31 2013-08-08 Unilever Plc Composition de soins personnels
US20130303631A1 (en) * 2012-05-11 2013-11-14 Conopco, Inc., D/B/A Unilever Environmentally Friendly and Aerated Topical Benefit Composition
EP3368000A1 (fr) * 2015-10-26 2018-09-05 Basf Se Procédés et produits pour l'hygiène buccale comprenant hlp
EP3243894A1 (fr) * 2016-05-10 2017-11-15 The Procter and Gamble Company Composition de nettoyage
JP2020534261A (ja) * 2017-09-08 2020-11-26 ザ ユニバーシティ オブ ブリストル 膜へのタンパク質送達
WO2019094913A2 (fr) 2017-11-13 2019-05-16 The Procter & Gamble Company Composition de soins personnels
WO2019190531A1 (fr) * 2018-03-29 2019-10-03 Sanova Bioscience, Inc. Films cosmétiques à base de collagène à dissolution rapide et leurs procédés
PL3958835T3 (pl) * 2019-04-24 2023-09-18 Follicum Ab Preparat do stosowania miejscowego
FR3109526B1 (fr) * 2020-04-22 2022-05-13 Elegant Best Investment Ltd Démaquillant moussant
CN113121666B (zh) * 2021-03-10 2023-09-12 厦门大学 抗菌肽Scybaumancin105-127及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2399161A (en) * 1942-06-30 1946-04-30 Claude R Wickard Process for producing glues and adhesives from keratin protein materials
GB1278924A (en) * 1970-02-06 1972-06-21 Ici Ltd Improvements in synthetic film materials
DE2609104A1 (de) * 1976-03-05 1977-09-15 Basf Ag Verfahren zur herstellung von styrol-suspensionspolymerisaten
DE2638839A1 (de) * 1976-08-28 1978-03-02 Basf Ag Verfahren zur herstellung von styrol-suspensionspolymerisaten
US5049504A (en) * 1986-11-24 1991-09-17 Genex Corporation Bioadhesive coding sequences
JPS6323670A (ja) * 1986-04-25 1988-01-30 バイオ−ポリマ−ズ　インコ−ポレ−テツド 接着・被覆組成物とその使用方法
DE4024871A1 (de) * 1990-08-06 1992-02-13 Basf Ag Perlfoermige antistatische expandierbare styrolpolymerisate
DE4220225A1 (de) * 1992-06-20 1993-12-23 Basf Ag Verfahren zur Herstellung von perlförmigen expandierbaren Styrolpolymerisaten
DE69310339T2 (de) * 1993-02-19 1997-08-21 Philippe Djian Präparate, die Corneozyt Proteine enthalten
IL110938A (en) * 1994-09-12 2001-01-28 Haber Meir Adhesive proteins isolated from mature macro and microalgae
AU5914196A (en) * 1995-06-12 1997-01-09 Proefstation Voor De Champignoncultuur Hydrophobins from edible fungi, genes, nucleotide sequences and dna-fragments encoding for said hydrophobins, and expression thereof
US6572845B2 (en) * 1998-10-16 2003-06-03 Burt D. Ensley Recombinant hair treatment compositions
DE19956802A1 (de) * 1999-11-25 2001-06-13 Cognis Deutschland Gmbh Waschmitteltabletten
GB0002663D0 (en) * 2000-02-04 2000-03-29 Biomade B V Method of stabalizing a hydrophobin-containing solution and a method of coating a surface with a hydrophobin
GB0002660D0 (en) * 2000-02-04 2000-03-29 Biomade B V Method of stabilizing a hydrophobin-containing solution and a method of coatinga surface with a hydrophobin
JP2002363026A (ja) * 2000-06-02 2002-12-18 Nihon Kolmar Co Ltd 化粧剤の吸着を増強させる方法および化粧料
US20030049726A1 (en) * 2000-09-06 2003-03-13 Holloway James L. Human phermone polypeptide
FR2833490B1 (fr) * 2001-12-14 2004-12-10 Oreal Utilisition cosmetique d'au moins une hydrophobine pour le traitement des matieres keratiniques et compositions mises en oeuvre
DE10342794A1 (de) * 2003-09-16 2005-04-21 Basf Ag Sekretion von Proteinen aus Hefen
US20080075684A1 (en) * 2004-05-24 2008-03-27 Basf Aktiengesellschaft Keratin-Binding Polypeptides
DE102004025805A1 (de) * 2004-05-24 2005-12-29 Basf Ag Keratin-bindende Effektormoleküle
US7241734B2 (en) * 2004-08-18 2007-07-10 E. I. Du Pont De Nemours And Company Thermophilic hydrophobin proteins and applications for surface modification
JP5250264B2 (ja) * 2005-02-07 2013-07-31 ビーエーエスエフ ソシエタス・ヨーロピア 新規ハイドロフォビン融合タンパク質、その製造および使用
DE102005027139A1 (de) * 2005-06-10 2006-12-28 Basf Ag Neue Cystein-verarmte Hydrophobinfusionsproteine, deren Herstellung und Verwendung
DE102005029704A1 (de) * 2005-06-24 2007-01-11 Basf Ag Verwendung von Hydrophobin-Polypeptiden sowie Konjugaten aus Hydrophobin-Polypeptiden mit Wirk-oder Effektstoffen und ihre Herstellung sowie deren Einsatz in der Kosmetik

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006136607A2 *

Also Published As

Publication number Publication date
WO2006136607A2 (fr) 2006-12-28
CA2612458C (fr) 2014-03-11
CN101203207A (zh) 2008-06-18
JP5452916B2 (ja) 2014-03-26
CN101203207B (zh) 2013-03-13
JP2014055149A (ja) 2014-03-27
JP2009501701A (ja) 2009-01-22
CA2612458A1 (fr) 2006-12-28
US20090136433A1 (en) 2009-05-28
WO2006136607A3 (fr) 2007-05-31
DE102005029704A1 (de) 2007-01-11

Similar Documents

Publication Publication Date Title
EP1898871A2 (fr) Utilisation de polypeptides d'hydrophobine et de conjugues de polypeptides d'hydrophobine avec des substances actives ou a effet ainsi que leur production et leur application en cosmetique
WO2005115306A2 (fr) Polypeptide liant la keratine
WO2008055931A1 (fr) Utilisation de résilines naturelles, recombinantes et synthétiques en cosmétique
EP1979055A2 (fr) Utilisation de microbilles de proteines dans le domaine cosmetique
WO2007060117A2 (fr) Proteines effectrices chimeres se liant a la keratine
EP1968642A2 (fr) Procede pour coupler des polypeptides se liant a la keratine, a des molecules effectrices portant des groupes carboxyle ou des groupes acide sulfonique
EP1957525A2 (fr) Molecules de type effecteur liant la keratine, contenant des colorants reactifs
WO2006097432A2 (fr) Utilisation de polypeptides liant la keratine et fabrication
EP1957111A2 (fr) Procédé de production d'une molécule effectrice fixant la kératine
MX2008006673A (es) Metodo para acoplar polipeptidos que se enlazan a la queratina con moleculas efectoras que soportan grupos carboxilicos o grupos de acido sulfonico

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080124

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080822

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160316